Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

INTRODUCTION: Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tate, Chandra R, Rhodes, Lyndsay V, Segar, H Chris, Driver, Jennifer L, Pounder, F Nell, Burow, Matthew E, Collins-Burow, Bridgette M
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446342/
https://ncbi.nlm.nih.gov/pubmed/22613095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3192
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars